We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -2.40 | -8.45% | 26.00 | 488,014 | 16:35:27 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 25.20 | 26.80 | 30.00 | 26.00 | 30.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 3.79M | -11.39M | -0.1639 | -1.64 | 18.62M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:07:45 | O | 25,000 | 26.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/11/2023 | 14:25 | ALNC |  TRADING UPDATES: SkinBio launches food supplement on Amazon |
| 30/11/2023 | 07:00 | UKREG | Oncimmune Holdings PLC Progress against Strategy |
| 10/11/2023 | 10:14 | UKREG | Oncimmune Holdings PLC Holding(s) in Company |
| 07/11/2023 | 16:11 | UKREG | Oncimmune Holdings PLC Grant of Options and PDMR Dealing |
| 19/10/2023 | 06:00 | UKREG | Oncimmune Holdings PLC Investor Presentation via Investor Meet Company |
| 12/10/2023 | 13:21 | ALNC | IN BRIEF: Oncimmune shares jump following new strategy update |
| 12/10/2023 | 06:00 | UKREG | Oncimmune Holdings PLC Update on Strategy & Changes to the Board |
| 01/8/2023 | 06:00 | UKREG | Oncimmune Holdings PLC Board Changes |
| 14/7/2023 | 13:00 | UKREG | Oncimmune Holdings PLC Corrected unaudited interim results to 31 May 2022 |
| 12/7/2023 | 10:14 | ALNC | Oncimmune names chief executive successor, while finance chief leaves |
Oncimmune (ONC) Share Charts1 Year Oncimmune Chart |
|
1 Month Oncimmune Chart |
Intraday Oncimmune Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/11/2023 | 14:09 | Oncimmune (ONC) cancer test diagnoses '80pc of tumours' early, savin | 283 |
| 23/1/2018 | 07:49 | Oncimmune (ONC) could save millions of lives | 2 |
| 20/2/2001 | 00:30 | Online Classics plc | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 17:07:45 | 26.00 | 25,000 | 6,500.00 | O |
| 16:33:22 | 26.80 | 65,000 | 17,420.00 | O |
| 12:34:04 | 26.20 | 108,000 | 28,296.00 | O |
| 10:31:41 | 26.65 | 15,000 | 3,996.90 | O |
| 09:52:57 | 26.65 | 42,500 | 11,324.55 | O |
| Top Posts |
|---|
Posted at 30/11/2023 08:20 by Oncimmune Daily Update Oncimmune Holdings Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker ONC. The last closing price for Oncimmune was 28.40p.Oncimmune currently has 69,475,000 shares in issue. The market capitalisation of Oncimmune is £18,619,300. Oncimmune has a price to earnings ratio (PE ratio) of -1.64. This morning ONC shares opened at 30p |
Posted at 12/10/2023 07:19 by brummy_git Encouraging new developments from IPR rich life science firm Oncimmune.All the details here. |
Posted at 31/5/2023 10:15 by eva_1989 I dont know what Trek from LSE smoking but i badly need same ;)He thought to pump before open so that he can sell to others... Hi R00st3R, I think todays interims answer your questions. All good at ONC. Well actually very good! Should be a cracking day today! Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment. Wish I could buy more at this price! Usual caveats Trek |
Posted at 31/5/2023 08:33 by brummy_git H1'23 results out today from Oncimmune. All the details here. |
Posted at 22/5/2023 08:26 by brummy_git Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.All the details here. |
Posted at 27/2/2023 07:13 by brummy_git Final results (y/e Aug'22) out today from global immunodiagnostics firm, OncimmuneAll the details here. |
Posted at 17/2/2023 08:56 by brummy_git Terrific news today from Oncimmune, who is partnering with with Siemens Healthineers to improve the assessment of indeterminate pulmonary nodules.All the details here. |
Posted at 22/12/2022 17:12 by brummy_git Excellent insights here from Oncimmune CEO Adam Hill - who takes me through the recent surge in new orders, £2.1m top up fund raise and strategic options for the EarlyCDT Lung division.www.linkedin.com/pos |
Posted at 20/12/2022 07:22 by brummy_git More encouraging contract wins for leading immunodiagnostics firm, Oncimmune.All the news and investor commentary here. www.linkedin.com/pos |
Posted at 14/12/2022 15:33 by brummy_git Leading immunodiagnostics firm Oncimmune successfully competes a £2.1m top up fund raise. All the details & commentary here.www.linkedin.com/pos |
Posted at 05/5/2021 06:15 by someuwin 5 May 2021Oncimmune Holdings plc ("Oncimmune" or the "Company") Return of China Rights to EarlyCDT product portfolio Enables strategic optionality to support access to the US capital markets Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group , today announces that it has successfully agreed to acquire the intellectual property (IP) and distribution rights for the EarlyCDT (R) technology in the People's Republic of China (PRC) and Hong Kong (HK) from Genostics Company Limited (Genostics), allowing the Company to pursue the optimum route to market in this important territory. Since granting Genostics the exclusive rights to EarlyCDT products in the PRC and HK in January 2018, Oncimmune and Genostics have collaborated to develop a lung panel with superior performance in Greater China and Asia-Pacific, given the prevalence of EGFR-positive non-small cell lung cancer (NSCLC) in the region. The Asia-specific lung panel has been used in a multi-centre study, previously announced on 10 May 2019, and which is now due to complete in China in H1 2021. Data from this study are intended to be used to support approval by the China National Medical Products Administration (NMPA) for the use of the Asia-specific lung cancer test in the PRC. Under the agreement announced today, all material, IP, data, and goodwill will be transferred back to the Company, and Oncimmune will be paid in full for the royalties due in January 2021 under the existing Technology Licencing Agreement. In consideration, Oncimmune has agreed to pay a fixed amount for the return of the IP and distribution rights, with the majority of the value of the consideration being conditional on fixed future events. With accelerating growth of Oncimmune's ImmunoINSIGHTS business, the Company intends to explore options available to it to access the US capital markets in the near term. The termination of Oncimmune's partnership with Genostics and return of the EarlyCDT product rights to the PRC and HK markets provides Oncimmune with further strategic optionality which could support a path to the US capital markets. As part of the agreement, and as previously announced, Genostics has agreed to a lock-in of its remaining shareholding in Oncimmune (currently 4.73 per cent. of the issued share capital) for a period of 12 months from 6 May 2021, except under certain limited exceptions. Dr Adam M Hill, CEO of Oncimmune said: " We are grateful for the collaboration with Genostics and its parent company, Gene Group Holdings Ltd, over the past three years and are pleased with the progress that has been made with our Asia-specific lung panel. However, as both companies consider their future on different equity capital markets, the continuing success of the EarlyCDT product portfolio, both in and outside of PRC and HK, requires Oncimmune to own the IP and distribution rights. We are delighted that Genostics has agreed to continue to participate in Oncimmune's success as a shareholder, and Oncimmune looks forward to progressing its market access plans imminently." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
